Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design

Abstract ESK‐001 is a highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2), which plays an essential role in mediating cytokine signaling in multiple immune‐mediated diseases. In 2 phase I studies, a first‐in‐human single ascending dose (SAD) and multiple ascending dose (MAD) study and...

Full description

Saved in:
Bibliographic Details
Main Authors: Sibel Ucpinar, Joyce K. Kwan, Joshua D. Hoffman, Mera K. Tilley, Jeffrey A. Douglas, Roman G. Rubio, Ruixiao Lu, Philip A. Nunn, Claire L. Langrish
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.70094
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items